Alkermes plc (ALKS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Dublin, Ireland. Der aktuelle CEO ist Richard F. Pops.
ALKS hat IPO-Datum 1991-07-16, 1,800 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $5.64B.
Alkermes plc is a biopharmaceutical company headquartered in Dublin, Ireland, that researches, develops, and commercializes pharmaceutical products to treat unmet medical needs across multiple therapeutic areas. The company's marketed portfolio includes ARISTADA and RISPERDAL CONSTA for schizophrenia, VIVITROL for alcohol use disorder and opioid dependence prevention, INVEGA SUSTENNA and related products for schizophrenia and schizoaffective disorder, and VUMERITY for relapsing forms of multiple sclerosis. Alkermes is also advancing pipeline candidates including LYBALVI, an oral atypical antipsychotic for schizophrenia and bipolar I disorder, and nemvaleukin alfa, an engineered immunotherapy designed to enhance anti-tumor immune responses. The company maintains significant collaboration agreements with Janssen Pharmaceuticals and operates across the United States, Ireland, and international markets.
